Oncology Drug Approval News Flash: FDA Approves Sonrotoclax (Beqalzi, BeOne Medicines) for Relapsed/Refractory Mantle Cell Lymphoma

On May 13, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sonrotoclax (Beqalzi^®, BGB-11417), an oral BCL-2 inhibitor developed by BeOne Medicines (formerly BeiGene), for adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) following at least two prior lines of systemic therapy including a BTK inhibitor. Sonrotoclax is the second oncology-approved BCL-2 inhibitor following venetoclax, and represents the first BCL-2 inhibitor approved as monotherapy in MCL. The approval introduces a new mechanistic option for post-BTKi R/R MCL — a clinical setting historically characterized by limited durable responses. This article summarizes the pivotal data, safety profile, and regulatory and clinical significance.

Target Patient Population

• Adults (≥18 years) with histologically confirmed mantle cell lymphoma
• Relapsed or refractory after at least two prior lines of systemic therapy including a BTK inhibitor
• Performance status compatible with oral therapy (typically ECOG 0–2)
• Adequate hepatic and renal function for oral dosing

Pivotal Trial Overview

The approval is supported by the integrated MCL monotherapy cohorts from BGB-11417 development trials, principally BGB-11417-103 (NCT04277637) and the Phase 2 BGB-11417-203 study. Both are open-label, single-arm, early-phase studies evaluating sonrotoclax safety, pharmacokinetics, and antitumor activity in B-cell malignancies, with MCL cohorts as a key indication.

Sonrotoclax is a next-generation, highly selective and high-affinity oral BCL-2 inhibitor. In vitro, its binding affinity for BCL-2 is reported to be roughly tenfold higher than venetoclax, and its plasma half-life is shorter. These properties were positioned during development as enabling (1) deeper BCL-2 inhibition with the potential for deeper responses, and (2) more manageable tumor lysis syndrome (TLS) risk given a shorter exposure window per dose.

To manage TLS risk, dosing follows a five-week stepwise ramp-up (80 mg → 160 mg → 320 mg). Outpatient monitoring is required during ramp-up, with the maintenance dose of 320 mg once daily achieved thereafter.

Key Efficacy Results

The integrated R/R MCL monotherapy cohort (N≈125, post-BTKi) supporting this approval showed the following key outcomes at a data cut-off in late 2025.

In post-BTKi R/R MCL, chemoimmunotherapy ORRs typically fall in the 20–30% range, and pirtobrutinib (the non-covalent BTKi) has been reported at roughly 50% ORR. Sonrotoclax’s ORR of approximately 70% with a CR rate near 50% represents a clinically meaningful depth-of-response improvement in this setting and supports its value as a new mechanistic alternative.

This is an accelerated approval, with confirmatory evidence dependent on ongoing randomized Phase 3 studies (BGB-11417-301 and related programs) that compare sonrotoclax-containing regimens against standards of care.

Safety Profile

Adverse events were dominated by toxicities characteristic of the BCL-2 inhibitor class — cytopenias, infections, and TLS — manageable with attention to monitoring and supportive care.

The label carries a prominent warning regarding tumor lysis syndrome, requiring (1) stepwise dose ramp-up, (2) inpatient monitoring for patients at high TLS risk (high tumor burden, renal impairment), (3) prophylactic hydration and uric-acid lowering, and (4) frequent monitoring of electrolytes, LDH, uric acid, and renal function during ramp-up. A Boxed Warning is not assigned, but TLS-related precautions feature prominently in the prescribing information.

Infection risk reflects BCL-2-inhibition-related B-cell depletion compounded by humoral immune compromise from prior MCL therapy. Consideration of CMV reactivation and PJP prophylaxis, and routine IgG monitoring, is recommended.

Regulatory and Clinical Significance

The clinical and regulatory implications can be summarized as follows.

(1) First BCL-2 inhibitor monotherapy approval in MCL. Venetoclax is approved in CLL and AML but not as monotherapy in MCL. Sonrotoclax is therefore the first BCL-2 inhibitor approved as a single-agent therapy in mantle cell lymphoma, providing a new mechanism for post-BTKi R/R disease.

(2) Reshaping the post-BTKi MCL treatment map. The post-BTKi R/R MCL landscape now contains CAR T-cell therapies (Tecartus, Breyanzi), the non-covalent BTKi pirtobrutinib, bispecific (CD20×CD3) antibodies, and now sonrotoclax. CAR-T offers deep responses but with substantial site and cost requirements; pirtobrutinib is convenient orally but with more limited depth. Sonrotoclax, with ORR ~70% and CR ~50% as an oral monotherapy, becomes a practical alternative for patients ineligible for CAR-T due to age, performance status, or geographic access.

(3) First clinical validation of a next-generation BCL-2 inhibitor. This approval is the first regulatory confirmation that a next-generation BCL-2 inhibitor can succeed where venetoclax was not previously labeled. Comparative trials in CLL and AML, and combinations with BTKi, anti-CD20 antibodies, and CAR-T consolidation, are now active and will determine whether sonrotoclax’s footprint expands. Approval status in other jurisdictions is determined separately and should be confirmed via local regulatory authorities.

My Thoughts and Future Outlook

The R/R MCL treatment map has been rewritten substantially over the past several years. BTKis came first, then non-covalent BTKis, then CAR T-cell therapies, then bispecifics, and now a next-generation BCL-2 inhibitor. The “what next after BTKi failure?” question, once a near-binary choice, has become a meaningfully layered decision. For patients, the expansion of options is unambiguously good news.

What that abundance creates, however, is the difficulty of sequencing. CAR-T followed by BCL-2 inhibition, or BCL-2 first to achieve response and CAR-T after? Continuation with sonrotoclax following pirtobrutinib failure, or a bispecific antibody first? Does the optimal post-BTKi-failure choice depend on the mechanism of BTKi resistance (C481S vs other)? Head-to-head comparative data to support these decisions are still limited, and clinical practice currently relies on experience and small-cohort signals. The years 2027–2028, as confirmatory trials read out, are likely to settle the next “stable state” of MCL therapy.

For the BCL-2 inhibitor class itself, this approval signals that generational succession is now plausible across CLL, AML, and MCL. Which next-generation agent ultimately replaces venetoclax in each indication — and over what timeframe — will be one of the more interesting class evolutions in the next two to three years. Beyond that, the unresolved scientific question of combining BCL-2 inhibition with MCL-1 or BCL-xL targeting remains the longer horizon, since chronic resistance through alternate BH3-family members continues to limit durable cures.

This article was compiled and summarized by Morningglorysciences based on FDA public materials, the BeOne Medicines press release, peer-reviewed publications of BGB-11417 trials, and related sources. Treatment decisions should always be made in reference to the original publications, the most recent prescribing information, and local clinical practice guidelines.